Method and devices for preventing restenosis in cardiovascular stents

Information

  • Patent Grant
  • 10610620
  • Patent Number
    10,610,620
  • Date Filed
    Monday, August 29, 2011
    12 years ago
  • Date Issued
    Tuesday, April 7, 2020
    4 years ago
Abstract
Devices and methods fabricating devices having nanostructures that allow adhesion or growth of one cell type, such as endothelial cells, more than another cell type, such as smooth muscle cells. In particular, stent covers may have nanostructures that allow adhesion or growth of one cell type more than another cell type. Nanostructures forming the devices may be optimized.
Description
INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety, as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.


BACKGROUND OF THE INVENTION

Stents have become the treatment of choice for a variety of blood vessel diseases in humans and are in common use worldwide. From the beginning of their use, it is known that an unacceptable percentage of cardiac stents become blocked after installation. This restenosis is a serious health problem: a patient may be more seriously impaired after treatment than before. Restenosis occurs when smooth muscle cells in the blood aggregate into clumps and cause the stent to become occluded. Drug-eluting coatings have been used to prevent clumping. Based on current data, it now appears that these coatings are not a satisfactory solution. For example, coated stents have been shown to cause blood clots several years after installation (Brian Vastag, “Stents Stumble,” Science News, Jun. 23, 2007 Vol. 171, pp 394-395). A patient receiving a coated stent must use blood thinners to prevent formation of blood clots that may dislodge from the region of the stent and cause stroke or heart attack. If the blood thinning treatment is interrupted, the probability of stroke is greatly increased. Thus, coated stents have therefore proved not to be a viable solution to the problem of stent restenosis.


It has recently been proposed that the restenosis of a stent is largely determined by whether the first layer of cells to grow on the surface of a stent are endothelial cells or smooth muscle cells (Julio Palmaz, Lecture at SMST conference 2003, Asilomar Calif. Comments not included in Proceedings of the conference). Described herein are stent covers which selectively enable endothelial cells to grow on their surface in comparison to smooth muscle cells, as well as methods of manufacturing and using them.


Other methods of preventing restenosis have been developed. For example, Palmaz describes a method using chemical affinities (resulting from charges on the surface of the stent) to regulate the growth of endothelial cells versus smooth muscle cells. U.S. Pat. No. 6,820,676 to Palmaz et al. teaches the use of surface relief patterns corresponding to crystal boundaries in metal to the enhance growth of cells. However, these patterns are irregular in size and shape and so are not ideally selective for a specific protein. In WO07078304A2, Dubrow et al. suggest using fibers (e.g., nanofibers or nanowires) to form a substrate for use in various medical devices.


Stents using shape memory alloys (e.g., Nitinol) to form thin-film stent covers are currently being developed. For example, US 2008/0161936 to Feller et al. describes a stent including a thin-film of shape memory alloy having different porosities in the deployed and undeployed configurations. A stent cover is typically placed over a stent to provide protection against debris that may be dislodged during installation of the stent. Described herein are stents or stent covers including a thin film coating or surface that preferably selects endothelial cells (e.g., from the blood stream) to grow on the inside surface of a thin-film stent or stent cover compared to other cell types (e.g., smooth muscle cells). This may be accomplished by forming nanostructures on the inside of the stent or stent cover. These nanostructures may be formed of one or more layers, and may correspond to recurring patterns on endothelial cell membrane proteins. Endothelial cells that come in contact with the surface nanostructures may selectively adhere to them. For example, endothelial cells (as opposed to smooth muscle cells) may ‘recognize’ the surface structure by pattern matching (or pattern recognition) and adhere. This pattern recognition step is a key element in many molecular biology processes. The devices and methods described herein take advantage of this native molecular biological process (e.g., cell-surface interactions) to influence the adherence of one type of cell (e.g. endothelial cells) in preference to other types (e.g. smooth muscle cells). Thus, surface nanostructures may be used to selectively enhance adhesion of endothelial cells over smooth muscle cells.


SUMMARY OF THE INVENTION

General methods of forming thin-film, nano-scale layered substrates appropriate for controlled cell growth are described herein. In addition, we describe particular applications of such nano-layered controlled growth substrates. In particular, described herein are implantable medical devices having nanostructures that allow adhesion and/or growth of one cell type, such as endothelial cells, more than another cell type, such as smooth muscle cells. For example, stents and stent covers having such nanostructures are described. Methods for fabricating these devices are also described.


For example, described herein are methods of controlling the growth of cells, including differential or preferential growth of cells, including the steps of patterning a substrate to have an organized nanostructure for cell growth, and placing cells on the patterned substrate. Cells may be regulated or controlled in any number of ways by the nanostructured surfaces described herein, including, as mentioned, differential growth (e.g., of various different cell types), cell guidance (e.g., axon guidance, cell migration, etc.), apoptosis, inhibition of cell growth, and the like.


A substrate may be patterned by: (a) layering a first nanostructural material at least partially over a substrate; (b) layering a second nanostructural material at least partially over the layer from step a; (c) repeating steps a and b to form a plurality of alternating layers of the first nanostructural material and the second nanostructural material; (d) forming a patterned layer on the outer surface of the plurality of alternating layers; and (e) etching the nonstructural material to form a nanostructured surface. In some variations, the step of layering the second nanostructural material comprises depositing a shape memory alloy at least partially over the first nanostructural material layer. The shape memory alloy may also be crystallized.


In general, these substrates are different from other cell culture substrates because they are formed using lithographic procedures to have sides or walls that are alternating layers or striated layers, of nanostructural materials (e.g., metals, alloys, polymers, etc.) that can be repeated patterns may layers thick. For example, one well or islet may have walls comprising five, ten, fifteen, twenty, twenty-five, fifty or even a hundred or more alternating layers of nanostructural materials. Each layer (or sub-layer) may be extremely thin (e.g., on the order of a few nm of thickness), and differ layers may have different thicknesses. The geometry may be important. For example, not only the thickness of each layer (or sub-layer), but the overall shape of the well or islet formed, as described in further detail below, may affect the growth or development of the cells contacting them.


For example, a method of forming a stent cover having a nanostructure includes the steps of forming a protective patterned layer on an outer surface of a sacrificial mandrel, layering a first nanostructural material at least partially over the protective patterned layer, depositing a shape memory alloy at least partially over the nanostructural material layer, crystallizing the shape memory alloy, removing the sacrificial mandrel, and etching the nonstructural material to form a nanostructured surface surrounded by a shape memory alloy thin film.


Any appropriate shape memory alloy may be used, including a nickel-titanium alloy (e.g., Nitinol), and the method may also include the step of fenestrating the shape memory alloy.


The sacrificial mandrel may be formed of an etchable metal, such as copper, that may be removed prior to etching the nanostructured layer. A protective patterned layer may be formed on the mandrel in order to pattern the nanostructural layer by acting as a resist layer to protect it (or a portion of it) during processing to form the nanostructural layer, particularly when the processing includes lithographic processing to form the nanostructural layer. The protective patterned layer may itself be formed on the mandrel photolithographically. For example, the protective patterned layer may be formed by coating a chromium layer on the sacrificial mandrel, applying a photoresistive layer, and then exposing it to a negative or positive of the desired protective pattern. For example, the protective patterned layer may be a checkerboard pattern to form islets of nanostructural material. In some variations, a pattern of wells may be formed.


Any appropriate material may be used as the nanostructural material. For example, the nanostructural material may include metals (including alloys), ceramics, polymers (including biopolymers), peptides (including polypeptides), nucleotides, composite materials, or the like. The nanostructural material may be a core matrix that is doped with additional materials. In some variations, the nanostructural material may be selected from the group consisting of: Ti, TiNi, Au, Ni, Al, Fe, Pt, Hf. Other materials having specific properties may be used, including those taught by Haushalter (U.S. Pat. No. 7,229,500). In some variations, the nanostructured layer includes a plurality of layers (including sub-layers). For example, a second nanostructural material may be at least partially applied over the protective patterned layer. The first nanostructural material may be applied to a thickness of between about 10 nm and about 500 nm. Similarly the second nanostructural material may be applied to a thickness of between about 10 nm and about 500 nm.


Also described herein are stent covers including nanostructures to which endothelial cells adhere preferentially compared to smooth muscle cells. A stent cover may include a thin-film of a shape memory material, the thin film at least partially surrounding a nanostructural layer, wherein the nanostructural layer comprises a layered nanoscale pattern having a shape and thickness that is selected so that endothelial cells preferentially adhere to the nanostructural layer as compared to smooth muscle cells.


As mentioned above, the shape memory material may be a nickel-titanium alloy (e.g., Nitinol). The shape memory material may further comprise fenestrations.


In some variations, the nanostructural layer comprises one or more pairs of sub-layers wherein each sub-layer is between about 10 nm and about 500 nm thick. The nanostructural layer may be at least partially made of a metal selected from the group consisting of: Ti, TiNi, Au, Ni, Al, Fe, Pt, Hf, and may have a thickness of between about 10 nm and about 500 nm. In some variations, the nanostructural layer comprises one or more sub-layers having a thickness of between about 10 nm and about 500 nm. Other materials having specific properties may be used, including those taught by Haushalter (U.S. Pat. No. 7,229,500).





BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:



FIG. 1A shows a layout of a patterned wafer and FIGS. 1B and 1C illustrates examples of types of patterns for cell growth.



FIGS. 2A-2D show various etched patterns of Ti—Ni—Ti multi-layers on a substrate.



FIG. 3 is a schematic diagram illustrating one variation of a method for forming a stent cover, as described herein.



FIG. 4A is a test wafer on which a nanostructure has been formed.



FIG. 4B is a detailed view of a region of the wafer of FIG. 2A.



FIGS. 4C and 4D are cross-sectional views showing nanostructures.



FIG. 4E shows cross-sectional views of a nanostructured substrate in accordance with an embodiment of the disclosure.





DETAILED DESCRIPTION OF THE INVENTION

Substrates, devices incorporating substrates, methods of forming substrates, and methods of forming devices including the substrates are described herein. In general, these substrates may be useful for tissue engineering. Surfaces such as those described herein that include structures having well-controlled shapes and sizes may provide means for controlling the behavior of individual cells and collections of cells (including tissues). Cells, and even tissues, may be controlled by controlling the arrangement of proteins.


Substrates including the patterned surfaces described herein (including those patterned using shape-memory materials) may provide surfaces on which controlled cell growth is enabled. These surfaces may be configured to select for cell type (e.g., enhancing the growth of certain cells compared to other cells). The structure of the surface may be the primary factor in regulating the cell behavior, rather than the chemical or material properties of the surface, as is commonly believed. The structure of the surface may also help manipulate the proteins on the surface of the cells and/or in the intracellular compartments of the cell.


The surface structures described herein are controlled over the dimension of the nanometer-to-micron scale. This scale (including the scale of the thickness of the layers) may be selected and controlled in a range of tens of nanometers to hundreds of nanometers, which is comparable to the size of most proteins. The scale of the micromachined structures (e.g., microns to tens of microns) is commensurate with the size of most cells. Thus, the methods described herein may allow the selection of proteins, which may be specific to certain types of cells, and of cell size and shape, which may also be specific to certain cell types. Taken together, these two selection methods may be much stronger than selection by either method alone. Unlike existing methods, which rely primarily on abrasion and have little or no control of the shape/size/pattern of the structures formed, these methods may create ordered and predictable patterns of surface structures having a predetermined shape and size. Typically, the layers forming the surfaces described herein are controlled to one percent or better.


The methods described herein may be used to create surfaces having organized arrangements of shapes. The shapes may be chosen based on the effect that the shape will have on cell behavior. For example, an elongated shape may encourage cell division (i.e., mitosis). A round shape may cause cells to undergo apoptosis (i.e., cell death). Other shapes may have different effects, such as encouraging migration or secretion. The thickness or shapes on the substrates described herein may also modify the expression of proteins on the surface of cells. For example, ledges that are of the same thickness dimension as a particular protein may enable formation of protein structures that do not occur in nature. A protein may bind to the surface in such a way that it is elongated rather than folded. If many proteins lie adjacent to each other in a stretched-out configuration, they may resemble (and may form) a novel crystal structure.


As mentioned, these substrates may be useful for growing tissues and organs. The location and spatial arrangement of individual cells in a multi-cell pattern may provide the scaffolding for development of specialized tissues.



FIGS. 1A-2D illustrate exemplary substrates, including patterns. These nano layered substrates may provide nanometer scale structures for use in cell growth experiments, for clinical cell growth, and for virtually any cell culture purpose. Furthermore, such surfaces may be included as part of a medical device (e.g., implant) or other medical interface, as described in greater detail below.


For example, FIG. 1A shows an exemplary pattern that may be formed on a silicon wafer or slide. In this example a thin film consisting of alternating layers of two materials (e.g., TiNi and Ti) are formed on a silicon die (slide). In this example, each layer may be vacuum sputter deposited to a thickness of between 10 and 250 nm. The thickness may be tightly controlled (e.g., a thickness of 10 nm for that layer may be approximately uniform at 10 nm), or it may be allowed to increase (e.g., ramp increase) across the layer. The actual thickness applied to the layer may be selected from the range (e.g., 10 to 250 nm) so that the final thickness is precisely known. Further, the number of layers formed of each material (e.g., TiNi, Ti, etc.) may be controlled. Typically multiple layers (e.g., 5 layers of each material, 10 layers of each material, 20 layers of each material, 30 layers of each material, etc.) may be chosen. The number of layers and the thickness of the layers may help form the complete thickness of the wells. As described in greater detail below, the side surfaces formed by these alternating layers (which may provide a striated or stratified side surface) may further create an ordered surface for cell or tissue growth. The different layers may be alternated in any desired pattern.


After deposition, wells may be created in the thin film by photolithographic techniques, including chemical etching. Wells may be between 1 and 10 microns in extent. The wells may have varying shapes and sizes to provide a variety of attachment conditions for cell development. FIG. 1A illustrates one example of a layout of a pattern on a wafer as viewed from the “macro” (naked eye) scale. Each horizontal line in this example indicates a row of one type of pattern. FIGS. 1B and 1C show different patterns that may be used. The images shown in FIGS. 1B and 1C are enlarged to show the shapes.


For example, the wafer shown in FIG. 1A may be divided up into 20 mm×20 mm slides. Each slide has approximately 50 rows of approximately 20 wells. In FIG. 1B, the rows (which may be included in the slide) have rectangular openings, and in FIG. 1C the rows five circular openings. The scale of these openings is between about 10 and about 400 microns in diameter. For example, the circles in FIG. 1C range in diameter from 10 to 200 microns (e.g., 10, 20, 40, 100, and 200 microns).



FIG. 2A-2D shows images of patterns etched in TiNi—Ti multi-layers on a silicon wafer, as briefly described above. For example, FIG. 2A shows a row of repeated rectangular openings. In one example, four groups of rectangular openings may be patterned. For example, the groups may be 10 microns wide by 100, 200, 300, and 400 microns long, 20 microns wide by 100, 200, 300, and 400 microns long, 40 microns wide by 100, 200, 300, and 400 microns long, and 80 microns wide by 100, 200, 300, and 400 microns long. The nanolayered substrates shown in FIGS. 2A-2C illustrate patterning of twenty alternating layers of Ti and TiNi deposited on a silicon or silicone oxide wafer surface to form a thin film that is 2 microns thick. The patterns of circles or rectangles can then be etched through the film. FIG. 2D shows an SEM image of a portion of an etched shape. The “walls” forming the shape are formed of the multiple layers of material, in this example, alternating layers of TiNi and Ti. The walls may be more or less ‘steep’ by controlling the etching or removal of the materials, and/or masking or protecting etched layers.


This general technique for forming a surface by patterning a substrate may be applied to substrates having non-flat (e.g. curved, bent, cylindrical, etc.) surfaces. For example, a medical implant, such as a catheter, stent, or the like, may include a nanolayered surface that is patterned appropriately to encourage and/or discourage cell growth or other cell behaviors.


Described below are stent covers and methods of forming stent covers having a preferentially patterned surface. For example, a method for determining a pattern that preferentially favors endothelial cell adhesion over smooth muscle cell adhesion is described. Although these methods are described with particular reference to stent covers, they may also be applied to the surface (particularly the “inner” or luminal surface) of a stent itself, or other structures, including other medical devices. Further, these methods and devices are not limited to surfaces favoring endothelial cell growth over smooth muscle cells. Surfaces helping to control (including differential growth, inhibition, cell guidance, apotosis, etc.) of any appropriate cell type may be formed using the methods and systems described herein. The patterned surfaces described herein may also be referred to as nanostructured surfaces, nanostructured layers, or nanotextured surfaces.


One variations of the nanostructured surfaces descried herein includes patterned stent covers.


Method of Forming a Patterned Stent Cover


Referring to FIG. 3, a stent cover may be formed having a pattern preferential for adhesion of endothelial cells compared to smooth muscle cells.


The patterned stent covers described herein may be patterned in the appropriate size scale for preferential adhesion of endothelial cells. It is desired that the size be highly selective, providing a major advantage for endothelial cells to grow relative to smooth muscle cells. For example, the scale of the patterns described herein may be in the nanometer range (e.g., between 0.1 and 500 nm). It is believed that a regular pattern of 200 nm balls creates a surface that is selective for endothelial cells. (Derick C. Miller, Journal of Biomedical Materials Research, Part A, 81A, Issue 3, 678-684: cited in “Nanotechnology for Healing Damaged Vascular Tissues,” Thomas Webster, www.scitizen.com/screens/blogPage/viewBlog/, last viewed Jul. 20, 2007).


A nanostructured surface may be formed as a layer created on the inside of the tubular stent cover by forming a protective pattern (e.g., by masking or otherwise protecting the material), then depositing a layer or layers of material that will form the nanostructural surface, and forming the outer shape memory material around the protective pattern and deposited layers. Once the shape memory material has been sufficiently prepared (e.g., crystallized), the mandrel may be removed, and the nanostructural surface may be formed by etching the pattern using microlithography to etch around the protected material of the protective pattern.



FIG. 3 describes one exemplary method for forming a stent cover having a nanostructural inner surface that is selective for endothelial cells over smooth muscle cells. In FIG. 3, a sacrificial mandrel is first prepared 101. In general, a sacrificial mandrel is a form that may be removed (e.g., by etching, erosion, etc.) once the layers of the stent cover have been formed around it. Thus, the sacrificial mandrel may be similar is shape and dimension to the outer surface of a stent with which the cover will be used. The material of the sacrificial mandrel is typically removable or etchable. For example, the sacrificial mandrel may be formed of copper. See, for example, U.S. Pat. No. 6,923,829 Boyle et al. These procedures are well known in MEMS technology.


A protective pattern may then be formed around the outside of the mandrel 103. As mentioned above, the protective pattern (or protective layer) at least partially forms the pattern of the nanostructure by selectively protecting the material forming the nanostructural surface from etching. For example, the protective pattern may be made from a thin layer of chromium, e.g., 10-100 nm thick, that is laid down on a cylindrical substrate 103 and formed into a desired pattern. The protective pattern may be formed by photolithographic techniques, as known in the art. For example, the chromium layer may be coated with a photoresist material and patterned by exposing it to negative (or positive) of at least a portion of the nanostructural layer followed by removal of the unexposed photoresist, etching to remove unprotected chromium, and removal of the photoresist layer. In one variation the chromium layer forms the shape and pattern of islets of the nanostructural surface. For example, the chrome layer may be patterned with a checkerboard design, so that the islets forming the nanostructure will be columnar islets having a square cross-section (see, e.g., FIGS. 4A-4C). After forming the protective pattern, the material forming the nanostructural surface layer may be applied over the protective pattern 105.


For example, alternating layers of material may be deposited over the protective pattern, as taught by Haushalter (U.S. Pat. No. 7,229,500). These layers may be referred to as sub-layers of the nanostructured surface, and will form the nanostructured surface. Any appropriate material may be layered on the protective pattern to form the nanostructured surface. In particular, materials may be chosen based on their potential for encouraging adhesion and/or growth of endothelial cells selectively, compared to smooth muscle cells. For example, the material may be a metal or alloy, including (but not limited to): Ti, TiNi, Au, Ni, Al, Fe, Pt, and Hf. Other materials having specific properties may be used, including those taught by Haushalter (U.S. Pat. No. 7,229,500). In some variations, the material is a doped material that includes a predetermined amount of some additional component. For example, the material forming a sub-layer of the nanostructured surface may be a metal or alloy that is doped with one or more transition elements, alkali (rare earth) metals, colloids, etc.


In some variations the layer of material forming the nanostructured surface includes a plurality of sub-layers of different materials. For example, the nanostructured surface may include repeated layers comprising two or more sub-layers. The material of each sub-layer may be different. The material properties of each sub-layer or layer may be different (e.g., hydrophobic/hydrophilic; +/−charge, etc.), in particular, there may be a difference in their rate of removal by a particular etchant. Thus, the materials forming the nanostructured surface may form one or more interfaces that can enhance attachment to endothelial cells, or inhibit attachment of smooth muscle cells. In some variations, the nanostructured surfaces include alternating sub-layers that may be differently etched to include recessed portions.


As mentioned, the sub-layers forming a nanosurface may be repeated. For example, a nanosurface may include a repeated motif of two or more sub-layers (e.g., sub-layer A and sub-layer B), that are repeated n times, so that the nanosurface comprises n layers of AB (or BA, depending on the order). The thickness of sub-layer A and sub-layer B may be uniform in each repeated layer, or the thicknesses may vary.


The dimensions of the nanostructured surface may be set by the combination of the pattern (e.g., the protective pattern), the thickness of the material(s) applied to form the nanostructured surface, and the etching used to form the nanostructural layer. In general, the nanostructured surface has dimensions that are within the nanometer scale (e.g., between 0.1 nm and 500 nm). For example, the nanostructured surface may be a repeated pattern of nanostructural “islets” having a predetermined depth (e.g., between 10 and 500 nm) and cross-sectional profile which matches the shapes formed of the protective pattern. For example, the islets may have square, rectangular, triangular, circular, oval, etc. shape. The predetermined depth of the islets may be determined by the thickness of the material(s) applied to the protective pattern on the mandrel (e.g., the thickness may be between 10 and 500 nm). The spacing between the islets may also be determined by the protective pattern (e.g., individual islets may be separated by between 10 and 500 nm, such as about 100 nm). In some variations, the nanostructure surface includes one or more wells etched to a shape and/or dimension as desired. For example, the wells may have a round, oveal, rectangular, or other shape, and may be between about 10 and 500 nm deep.


As mentioned, the shape, dimension and spacing of the islets/wells forming the nanostructure may be specifically chosen so that adhesion or growth of one cell type (e.g., endothelial cells) is favored in comparison to another cell type (e.g., smooth muscle cells). Thus, the shape, depth and arrangement of the islets/wells may be determined experimentally, as described in the examples below.


Returning now to FIG. 3, after the appropriate thickness of material forming the nanostructured surface has been applied 105, a layer of shape memory material is then applied 107. Any appropriate shape memory material may be used, particularly a shape memory alloy such as a nickel titanium alloy. One preferred material is Nitinol. The shape memory material is deposited as a thin film. When the desired thickness of thin film has been deposited, the material may then be heat-treated to crystallize 109. In some variations, the thin film layer shape memory material is then fenestrated (e.g., using standard MEMS photolithography). U.S. Pat. No. 6,533,905 to Johnson et al. describes one method of applying (e.g., by vacuum deposition including sputtering) a TiNi shape memory alloy as mentioned above, and a patterned stent cover may be made using some of the teachings described therein. For example, U.S. Pat. No. 6,533,905 may be exploited to make a tubular stent cover.


The thin layer of shape memory material may also be patterned. For example, the shape memory material may be fenestrated 111. Fenestrations may be biologically desirable (e.g., allowing access or in-growth).


The sacrificial substrate (e.g., the mandrel) may be removed, leaving a cylinder of thin film material (e.g., shape memory material) with a protective layer (e.g., chromium) and the layer(s) of materials that will form the nanostructured surface inside 113 the cylinder. The material forming the nanostructured layer(s) can be patterned by exposure to appropriate etchants 115.


The finished stent cover formed by the method of FIG. 3 is a fenestrated, tubular, thin film of shape memory material (e.g., Nitinol), inside of which is a surface consisting of nanostructures that have appropriately structures (e.g., layered islets) to selectively grow a layer of cell, including endothelial cells, preferentially to another type of cell, such as smooth muscle cells in the blood stream.


In general, materials (particularly the material or materials forming the nanostructured surface) must be selected for compatibility of the other steps of the method. For example, these materials must survive heat treatment without damage. Materials used must be compatible with deposition and processing of TiNi film, including crystallization at 500° C. Further, the etchants must be highly selective.


An assumption is made that there are different proteins in the cell membranes of smooth muscle cells than on endothelial cells. The experimental fact that endothelial cells grow preferentially on layers formed from spheres 200 nanometers in size appears to support this assumption (Thomas Webster, Nanotechnology for healing damaged vascular tissue, Nanomedicine Laboratories, Brown University, Providence R.I., www.scitizen.com).


A further assumption is that a repeating pattern of layers having an appropriate distance of repetition, each layer consisting of two or more sub-layers differing in some quality, will also act to enhance growth of endothelial cells. Since the appropriate distance is not known, it may be determined by experiment, as mentioned above. The examples below outline one method in which these parameters may be determined experimentally.


EXAMPLES
Optimizing a Nanoscale Pattern

As used here, the term “nanostructural pattern” may refer to a surface or layer having nanostructural features. In general, this is a surface having one or more repeated motifs of nanoscale structures. These nanoscale structures may be repeated “islets” etched from the one or more layers of material (or sub-layers) forming the nanostructural layer. Thus, the nanostructural layer may be a plurality of columnar islets separated from each other by a “street” or channel having a predetermined depth. A cross-section through an islet may be square, rectangular, circular, etc. The sides of an islet may present stratified layers made up of different materials, and the thickness (depth) of each layer (as well as the material from which the layer is made) may be chosen to select one type of cell over another type of cell (e.g., endothelial cells over smooth muscle cells). These islets may therefore present a larger surface area of interface boundaries between different materials which cells may contact. Certain cell types may preferentially adhere to some interface regions.


One or more nanostructural patterns that are selective for endothelial cells over smooth muscle cells may be determined experimentally using the methods and devices described herein. For example, U.S. Pat. No. 7,229,500 to Haushalter et al. describes a method of enhancing the crystallization of certain species of proteins by providing heterogeneous nucleation sites consisting of multiple nanometer scale thickness layers with alternating characteristics. The methods of the U.S. Pat. No. 7,229,500 patent may be adapted to form nanostructural patterns that may be tested to determine nanostructural layers (sub-layers) or patterns that preferentially support endothelial cells over smooth muscle cells. Nanometer scale, regular patterns of alternating layers and/or materials can be generated and systematically examined for interaction with both endothelial and smooth muscle cells, to determine which one or more regions of specific patterns may act as scaffolds for specific types of cell (e.g. endothelial cells) by causing their cell membrane proteins to adhere to the surface more strongly than other types of cells (e.g. smooth muscle cells). Successful application of this invention may result in a continuous layer of endothelial cells being formed on the surface of the stent cover.


In some variations, a library of different nanostructures (islets and/or wells) may be formed of layers of selected materials and thicknesses, so that the optimum thickness and materials can be determined to be selective for endothelial cells. FIGS. 4A-4C illustrates one variation of this. Initial experiments may be performed to determine whether endothelial cells can be separated from smooth muscle cells by graded thickness of metal on substrate. In one variation of this experiment, selectivity may be determined by varying the size scale.


Endothelial and smooth muscle cells may be grown on substrates with raised islets of graded varying thickness or with wells or depressions of various depths. The substrates may be inspected to see if cells grow preferentially on islets of a particular thickness and/or wells or a particular depth. The experiment may be performed by first preparing the substrate. In this example, the substrate is a wafer 201 onto which islets have been formed. The islets or wells (nanostructures) may be formed by sputter depositing one or more metal layers. The thickness of the metal layer may vary continuously from a few nanometers on one edge of wafer to about 500 nanometers on the other edge. After coating with layers of metal(s), the islets/wells may then be formed by patterning them by photolithography, and chemically milling them to produce regular patches or islets of metal, as shown in FIG. 4B, which is a close-up view of a region of the wafer 201 and 2C, which shows a cross-section through a wafer. In this example, islets 203 near one edge of the wafer are about 500 nm, and islets near other edge of the wafer are about 10 nm. Patterns in a particular region of a wafer may be kept uniform in length and width so that this is not a variable. For example, the cross-sectional shape of the islets on a particular wafer may be constant, even though the depth is varying. The size of islets may be varied from one wafer to another to test the effect of cross-sectional size. The cross-sectional shape (e.g., circular, polygonal—e.g., triangular, rectangular, square, etc.) may also be varied between wafers (or on a single wafer) to determine an effect. FIG. 4C illustrates a cross-section through a wafer (not to scale) showing exemplary islets having different thicknesses, e.g., from 10 nm (209) to 500 nm (207).


Different islet materials may also be tested. For example, different metals may be tested, including (but not limited to): Ti, TiNi, Au, Ni, Al, Fe, Pt, and Hf. In some variations, other materials may be used. In some variations, the layers of material may be doped with one or more molecules. For example, there are known cell-adhesion proteins that may be incorporated as part of the layered material. Other materials include transition elements, alkali or alkaline/rare earth materials, oxyacids, nitrates, acetates, sulfates, colloids, etc.


To test, pairs of wafers may be exposed to two different cell types, or a single wafer may be exposed to two different cell types (e.g., the wafer may be divided in half). For example, one wafer (or half a wafer) may be exposed to endothelial cells, while the other wafer (or half of the wafer) is exposed to smooth muscle cells. After an appropriate time, the wafers may be inspected to determine if there is a significant difference in the way the two types of cells adhere and/or grow. This method may help answer the question as to whether cells grow preferentially on a specific thickness of material, as well as which materials may be preferred. In particular, this type of experiment may help determine if there is a thickness and/or material to which endothelial cells adhere or grow better than smooth muscle cells.


The test wafers described herein may be formed on a glass substrate. For example, a 4-inch wafer having an oxidized surface (to present a smooth glass surface) may be used. A pair of wafers may each be identically deposited with the metal (or other material) in a thickness gradient from one side of the wafer to the other. For example, the thickness may be varied from 500 to 10 nanometers. Afterwards, the islets and/or wells may be patterned. In one variation, three patterns of islets/wells (having different cross-sectional sizes) may be formed per wafer. For example, a square profile islet having a length and width of 1 mm, 0.5 mm, or 0.1 mm may be formed on each wafer. The spacing between each islet (the street) may be about 100 nm wide. The islets may be patterned by photolithography using a prepared mask exposed to the coated surface of the wafer after applying a layer of photoresist. The exposed photoresit may then be removed, and the wafer etched. Afterwards, the wafer (including the formed islets) may be cleaned to remove all chemicals (etchant, etc.) from the wafer.


Cell growth or adhesion on the wafers may be tested in any appropriate way. For example, cell growth may be examined after incubating with cells or after exposing to flows of cells. Wafers can then be examined for successful growth, especially growth at a particular metal thickness. Statistics (cell counts, etc.) may be taken to quantify any effects.


The sensitivity of these experiments may be enhanced as part of a second phase of experiments. Selectivity can be increased by making nanostructures (e.g., islets, wells, etc.) having multiple layers, as shown in FIG. 4D. Different materials may be layered onto the wafer in alternating layers 211, 213, 215, 217. Materials having contrasting properties (e.g., hydrophilic/hydrophobic, charged/uncharged, +/−charges, doped/undoped, and/or different etching rates) may be of particular interest. Multiple-layered islets/wells may be formed similar to the method just described above, and similarly tested. In addition to tests against isolated cells, materials may be tested in an animal model. For example, rather than using a glass wafer as the test substrate, the substrate may be a nickel-titanium material. Thus, a testing stent or stent cover may be formed having varying characteristics for the nanostructures, as briefly described above, and implanted into an animal model for testing. This test stent cover or stent may be retrieved after an appropriate time, and histologically examined to determine which regions (corresponding to which nanostructures) had desirable properties with respect to endothelial versus smooth muscle cells.


The nanostructured layer may be formed of multiple layers or sub-layers of material, as described above and illustrated in FIG. 4D. In some variations, the nanostructured surface may be formed of multiple repeated sub-layers. For example, two layers can be repeated to form a layer that may be etched to form the nanostructured surface. The thicknesses of the two sub-layers may be varied in two gradients across the surface of the substrate. For example, the thickness of the first sub-layer can decrease from the left to the right of the substrate. The thickness of the second sub-layer can decrease from the back to the front of the substrate. The overall thickness of the nanostructured surface (the depth of each islet) may be kept approximately constant across the substrate (e.g., by increasing the number of layers applied). This substrate may be used to test the effect of the thicknesses of each sub-layer on cell adhesion and growth, as described above.


In addition to the thickness of the nanostructure-forming layer(s), the shape of the nanostructure(s) may also be varied. Differential etching may be used to form a superlatice having different interlayer spacing. For example, one or the sub-layers forming the nanostructured surface may be etched more than the other sub-layer(s), as shown in FIG. 4E. In FIG. 4E, the second (grey) sublayers etches more than the first (white) sublayers. This results in a nanotextured 3-D surfaces in which one of the sub-layers is undercut compared to the other sub-layer, forming indentations, pockets, ledges and/or terraces along the surface, as shown in FIG. 4E305, 307, 309, and 311. The amount of relative etching of each sub-layer can also be varied to determine the effect on cell adhesion and growth, as described above. For example, by varying the etching times and/or etch rates, different amounts of surface etching may be achieved.


Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Claims
  • 1. A thin-film stent cover comprising: the thin film stent cover applied to a surface of a stent, wherein the thin film stent cover comprising: a plurality of layers comprising a first layer of a first metal material, a second layer of the first metal material, and a third layer of a second metal material different from the first metal material, the third layer disposed between the first and the second layers; anda plurality of fenestrations, each fenestration formed through the plurality of layers by microlithography etching a first opening in the first layer, a second opening in the second layer and a third opening in the third layer, the first, second, and third openings are aligned to form a continuous fenestration through the plurality of layers,wherein the second metal material has a material property of a greater etch rate than the first metal material such that the third opening of the third layer is etched to be greater in size than a size of each of the first and second openings of the first and second layers by differential etching to form a recess between the first and second openings of the first and second layers within the continuous fenestration,wherein a thickness of at least one of the plurality of layers is varied in a gradient across a surface of the at least one of the plurality of layers, wherein the plurality of fenestrations form a nanostructural surface configured so that one type of cells preferentially adhere to the nanostructural surface as compared to another type of cells and/or the nanostructural surface is configured to facilitate adherence of cells to the nanostructural surface as compared to a surface without the nanostructural surface, andwherein each of the fenestrations has a size of between about 10 microns and about 400 microns.
  • 2. The thin-film stent cover of claim 1, wherein one of the first and the second metal materials comprises titanium alloy and the other of the first and second metal materials comprises nickel-titanium alloy.
  • 3. The thin-film stent cover of claim 1, wherein the first metal material and/or the second metal material comprise a metal selected from the group consisting of: Ti, TiNi, Au, Ni, Al, Fe, Pt, and Hf.
  • 4. A thin-film stent cover comprising: the thin film stent cover applied to a surface of a stent, wherein the thin film stent cover comprising: a plurality of layers comprising a first layer of a first metal material, a second layer of the first metal material, and a third layer of a second metal material different from the first metal material, the third layer disposed between the first and the second layers; anda plurality of wells, each well extending through at least a subset of the plurality of layers by microlithography etching a first opening in the first layer, a second opening in the second layer and a third opening in the third layer, the first, second, and third openings are aligned to form a continuous well through the subset of the plurality of layers,wherein the second metal material has a material property of a greater etch rate than the first metal material such that the third opening of the third layer is etched to be greater in size than a size of each of the first and second openings of the first and second layers by differential etching to form a recess between the first and second openings of the first and second layers within the continuous well,wherein a thickness of at least one of the plurality of layers is varied in a gradient across a surface of the at least one of the plurality of layers, wherein the plurality of wells form a nanostructural surface configured so that one type of cells preferentially adhere to the nanostructural surface as compared to another type of cells and/or the nanostructural surface is configured to facilitate adherence of cells to the nanostructural surface as compared to a surface without the nanostructural surface, andwherein the wells have a depth of between about 10 nm and about 500 nm.
  • 5. The thin-film stent cover of claim 4, wherein one of the first and the second metal materials comprises titanium alloy and the other of the first and second metal materials comprises nickel-titanium alloy.
  • 6. The thin-film stent cover of claim 4, wherein the first metal material and/or the second metal material comprise a metal selected from the group consisting of: Ti, TiNi, Au, Ni, Al, Fe, Pt, and Hf.
  • 7. A thin-film stent cover comprising: the thin film stent cover applied to a surface of a stent, wherein the thin film stent cover comprising: a plurality of layers comprising a first layer of a first metal material, a second layer of the first metal material, and a third layer of a second metal material different from the first metal material, the third layer disposed between the first and the second layers; anda plurality of raised islets, each raised islet formed by microlithography etching of a subset of the plurality of layers to form a first step in the first layer, a second step in the second layer and a third step in the third layer, the first, second, and third steps are aligned in a stack to form a raised islet;wherein the second metal material has a material property of a greater etch rate than the first metal material such that the third step of the third layer is etched to be smaller in size than a size of each of the first and second steps of the first and second layers by differential etching to form a recessed third step between the first and second steps of the first and second layers around the raised islet,wherein a thickness of at least one of the plurality of layers is varied in a gradient across a surface of the at least one of the plurality of layers, wherein the plurality of islets form a nanostructural surface configured so that one type of cells preferentially adhere to the nanostructural surface as compared to another type of cells and/or the nanostructural surface is configured to facilitate adherence of cells to the nanostructural surface as compared to a surface without the nanostructural surface, andwherein the raised islets have a thickness of between about 10 nm and about 500 nm.
  • 8. The thin-film stent cover of claim 7, wherein one of the first and the second metal materials comprises titanium alloy and the other of the first and second metal materials comprises a nickel-titanium alloy.
  • 9. The thin-film stent cover of claim 7, wherein the first metal material and/or the second metal material comprise a metal selected from the group consisting of: Ti, TiNi, Au, Ni, Al, Fe, Pt, and Hf.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 12/182,119, filed on Jul. 29, 2008, entitled “METHOD AND DEVICES FOR PREVENTING RESTENOSIS IN CARDIOVASCULAR STENTS”, which claims priority to U.S. Provisional Application No. 60/952,818 filed on Jul. 30, 2007, entitled, “METHOD AND DEVICES FOR PREVENTING RESTENOSIS IN CARDIOVASCULAR STENTS.”

US Referenced Citations (267)
Number Name Date Kind
368425 Ross et al. Aug 1887 A
538593 Naylor, Jr. Apr 1895 A
1560335 Czochralski Nov 1925 A
1904828 Green Apr 1933 A
1913035 Loepsinger Jun 1933 A
1926925 Wescott Sep 1933 A
2060593 Schaurte et al. Nov 1936 A
2371614 Graves Mar 1945 A
2586556 Mullikin Feb 1952 A
2608996 Forman Sep 1952 A
2610300 Walton et al. Sep 1952 A
2647017 Coulliette Jul 1953 A
2793036 Hansburg May 1957 A
2911504 Cohn Nov 1959 A
3229956 White Jan 1966 A
3351463 Rozner et al. Nov 1967 A
3357432 Sparks Dec 1967 A
3400906 Stocklin Sep 1968 A
3408890 Bochman, Jr. Nov 1968 A
3435823 Edwards Apr 1969 A
3445086 Quinn May 1969 A
3454286 Anderson et al. Jul 1969 A
3546996 Grijalva et al. Dec 1970 A
3559641 Lay Feb 1971 A
3561537 Dix et al. Feb 1971 A
3613732 Willson et al. Oct 1971 A
3620212 Fannon, Jr. et al. Nov 1971 A
3659625 Coiner et al. May 1972 A
3668131 Banush et al. Jun 1972 A
3725835 Hopkins et al. Apr 1973 A
3789838 Fournier et al. Feb 1974 A
3849756 Hickling Nov 1974 A
3888975 Ramwell Jun 1975 A
3913572 Wheeler Oct 1975 A
3918443 Vennard et al. Nov 1975 A
3974844 Pimentel Aug 1976 A
3991898 Hanson et al. Nov 1976 A
4055955 Johnson Nov 1977 A
4063831 Meuret Dec 1977 A
4072159 Kurosawa Feb 1978 A
4096993 Behr Jun 1978 A
4145764 Kuzuki et al. Mar 1979 A
4151064 Kuehnle Apr 1979 A
4176719 Bray Dec 1979 A
4177327 Mathews Dec 1979 A
4243963 Jameel et al. Jan 1981 A
4265684 Boll May 1981 A
4279190 Hummel Jul 1981 A
4340049 Munsch Jul 1982 A
4434855 Given, Jr. et al. Mar 1984 A
4485545 Caverly Dec 1984 A
4501058 Schutzler Feb 1985 A
4524343 Morgan et al. Jun 1985 A
4549717 Dewaegheneire Oct 1985 A
4551974 Yaeger et al. Nov 1985 A
4553393 Ruoff Nov 1985 A
4553602 Pieczykolan Nov 1985 A
4558715 Walton et al. Dec 1985 A
4567549 Lemme Jan 1986 A
4585209 Aine et al. Apr 1986 A
4589179 Hulting, Jr. May 1986 A
4596483 Gabriel et al. Jun 1986 A
4619284 Delarue et al. Oct 1986 A
4654191 Krieg Mar 1987 A
4684913 Yaeger Aug 1987 A
4706758 Johnson Nov 1987 A
4753465 Dalby Jun 1988 A
4821997 Zdeblick Apr 1989 A
4823607 Howe et al. Apr 1989 A
4824073 Zdeblick Apr 1989 A
4848388 Waldbusser Jul 1989 A
4854797 Gourd Aug 1989 A
4864824 Gabriel et al. Sep 1989 A
4893655 Anderson Jan 1990 A
4896728 Wolff et al. Jan 1990 A
4915773 Kravetsky Apr 1990 A
4943032 Zdeblick Jul 1990 A
5044947 Sachdeva et al. Sep 1991 A
5060888 Vezain et al. Oct 1991 A
5061137 Gourd Oct 1991 A
5061914 Busch et al. Oct 1991 A
5069419 Jerman Dec 1991 A
5072288 MacDonald et al. Dec 1991 A
5102276 Gourd Apr 1992 A
5114504 AduJudom, II et al. May 1992 A
5116252 Hartman May 1992 A
5117916 Ohta et al. Jun 1992 A
5119555 Johnson Jun 1992 A
5129753 Wesley et al. Jul 1992 A
5131843 Hilgers et al. Jul 1992 A
5160233 McKinnis Nov 1992 A
5190546 Jervis Mar 1993 A
5192147 McCloskey Mar 1993 A
5211371 Coffee May 1993 A
5218998 Bakken et al. Jun 1993 A
5245738 Johnson Sep 1993 A
5309717 Minch May 1994 A
5312152 Woebkenberg, Jr. et al. May 1994 A
5312247 Sachdeva May 1994 A
5325880 Johnson et al. Jul 1994 A
5344117 Trah et al. Sep 1994 A
5364046 Dobbs et al. Nov 1994 A
5395238 Andreiko et al. Mar 1995 A
5447432 Andreiko et al. Sep 1995 A
5456600 Andreiko et al. Oct 1995 A
5474448 Andreiko et al. Dec 1995 A
5474563 Myler et al. Dec 1995 A
5494113 Polan Feb 1996 A
5502982 Venetucci Apr 1996 A
5543349 Kurtz et al. Aug 1996 A
5605543 Swanson Feb 1997 A
5619177 Johnson et al. Apr 1997 A
5622225 Sundholm Apr 1997 A
5640217 Hautcoeur et al. Jun 1997 A
5641364 Golberg et al. Jun 1997 A
5645423 Collins, Jr. Jul 1997 A
5658515 Lee et al. Aug 1997 A
5676356 Ekonen et al. Oct 1997 A
5683245 Sachdeva et al. Nov 1997 A
5695504 Gifford, III et al. Dec 1997 A
5714690 Burns et al. Feb 1998 A
5722989 Fitch et al. Mar 1998 A
5771742 Bokaie et al. Jun 1998 A
5772378 Keto-Tokoi Jun 1998 A
5772864 Moller et al. Jun 1998 A
5796152 Carr et al. Aug 1998 A
5819749 Lee et al. Oct 1998 A
5825275 Wuttig et al. Oct 1998 A
5837394 Schumm, Jr. Nov 1998 A
5840199 Warren Nov 1998 A
5850837 Shiroyama et al. Dec 1998 A
5867302 Fleming Feb 1999 A
5903099 Johnson et al. May 1999 A
5916178 Noone et al. Jun 1999 A
5924492 Kikuchi et al. Jul 1999 A
5930651 Terasawa Jul 1999 A
5960812 Johnson Oct 1999 A
6013854 Moriuchi Jan 2000 A
6042374 Farzin-Nia et al. Mar 2000 A
6042553 Solar et al. Mar 2000 A
6072617 Henck Jun 2000 A
6073700 Tsuji et al. Jun 2000 A
6075239 Aksyuk et al. Jun 2000 A
6080160 Chen Jun 2000 A
6084849 Durig et al. Jul 2000 A
6096175 Roth Aug 2000 A
6101164 Kado et al. Aug 2000 A
6107004 Donadio, III Aug 2000 A
6110204 Lazarov et al. Aug 2000 A
6123153 Finnegan Sep 2000 A
6124523 Banas et al. Sep 2000 A
6126371 McCloskey Oct 2000 A
6129153 Joung Oct 2000 A
6139143 Brune et al. Oct 2000 A
6169269 Maynard Jan 2001 B1
6195478 Fouquet Feb 2001 B1
6203715 Kim et al. Mar 2001 B1
6224626 Steinke May 2001 B1
6229640 Zhang May 2001 B1
6247493 Henderson Jun 2001 B1
6277133 Kanesaka Aug 2001 B1
6284067 Schwartz et al. Sep 2001 B1
6352494 McAlonan Mar 2002 B2
6358380 Mann et al. Mar 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6386507 Dhuler et al. May 2002 B2
6406605 Moles Jun 2002 B1
6407478 Wood et al. Jun 2002 B1
6410360 Steenberge Jun 2002 B1
6419491 Ricci Jul 2002 B1
6447478 Maynard Sep 2002 B1
6451668 Neumeier et al. Sep 2002 B1
6454913 Rasmussen et al. Sep 2002 B1
6470108 Johnson Oct 2002 B1
6475261 Matsumoto et al. Nov 2002 B1
6524322 Berreklouw Feb 2003 B1
6533905 Johnson et al. Mar 2003 B2
6537310 Palmaz et al. Mar 2003 B1
6582985 Cabuz et al. Jun 2003 B2
6592724 Rasmussen et al. Jul 2003 B1
6596102 Homma Jul 2003 B2
6605111 Bose et al. Aug 2003 B2
6614570 Johnson et al. Sep 2003 B2
6620634 Johnson et al. Sep 2003 B2
6624730 Johnson et al. Sep 2003 B2
6669794 Bellouard et al. Dec 2003 B1
6669795 Johnson et al. Dec 2003 B2
6672502 Paul et al. Jan 2004 B1
6688828 Post Feb 2004 B1
6709379 Brandau et al. Mar 2004 B1
6729599 Johnson May 2004 B2
6742761 Johnson et al. Jun 2004 B2
6746890 Gupta et al. Jun 2004 B2
6771445 Hamann et al. Aug 2004 B1
6790298 Johnson et al. Sep 2004 B2
6805898 Wu et al. Oct 2004 B1
6811910 Tsai et al. Nov 2004 B2
6820676 Palmaz et al. Nov 2004 B2
6821638 Obeshaw Nov 2004 B2
6840329 Kikuchi et al. Jan 2005 B2
6843465 Scott Jan 2005 B1
6849085 Marton Feb 2005 B2
6852132 Houser et al. Feb 2005 B1
6908275 Nelson et al. Jun 2005 B2
6918545 Franson et al. Jul 2005 B2
6920966 Buchele et al. Jul 2005 B2
6923829 Boyle et al. Aug 2005 B2
6955187 Johnson Oct 2005 B1
7022173 Cummings et al. Apr 2006 B2
7040323 Menchaca et al. May 2006 B1
7044596 Park May 2006 B2
7073504 Callister et al. Jul 2006 B2
7084726 Gupta et al. Aug 2006 B2
7201367 Wietharn Apr 2007 B2
7229500 Haushalter et al. Jun 2007 B2
7235092 Banas et al. Jun 2007 B2
7235096 Van Tassel et al. Jun 2007 B1
7235098 Palmaz Jun 2007 B2
7422403 Johnson et al. Sep 2008 B1
7441888 Johnson Oct 2008 B1
7524914 Mather et al. Apr 2009 B2
7540899 Johnson Jun 2009 B1
7544257 Johnson et al. Jun 2009 B2
7586828 Xiaogdang Sep 2009 B1
7632361 Johnson et al. Dec 2009 B2
7736687 Sims et al. Jun 2010 B2
7763342 Johnson Jul 2010 B2
7793911 Fontana et al. Sep 2010 B2
7842143 Johnson et al. Nov 2010 B2
20010023010 Yamada et al. Sep 2001 A1
20020018325 Nakatani et al. Feb 2002 A1
20020062154 Ayers May 2002 A1
20020106614 Prince et al. Aug 2002 A1
20020192617 Phan et al. Dec 2002 A1
20030002994 Johnson et al. Jan 2003 A1
20030054578 Behfar Mar 2003 A1
20030078465 Pai et al. Apr 2003 A1
20030170130 Johnson Sep 2003 A1
20040083006 Ellingsen Apr 2004 A1
20040200551 Brhel et al. Oct 2004 A1
20040221614 Holemans et al. Nov 2004 A1
20040243219 Fischer et al. Dec 2004 A1
20040249399 Cinquin et al. Dec 2004 A1
20050112397 Rolfe May 2005 A1
20050113933 Carter et al. May 2005 A1
20060118210 Johnson Jun 2006 A1
20060204738 Dubrow et al. Sep 2006 A1
20060213522 Menchaca et al. Sep 2006 A1
20060240953 Shahinpoor Oct 2006 A1
20070134296 Burgermeister Jun 2007 A1
20070173787 Huang et al. Jul 2007 A1
20070207321 Abe et al. Sep 2007 A1
20070246233 Johnson Oct 2007 A1
20080075557 Johnson et al. Mar 2008 A1
20080161936 Feller et al. Jul 2008 A1
20080213062 Johnson Sep 2008 A1
20090029077 Atanasoska et al. Jan 2009 A1
20090035859 Johnson Feb 2009 A1
20090166318 Seitz Jul 2009 A1
20090183986 Johnson et al. Jul 2009 A1
20090187243 Johnson Jul 2009 A1
20100006304 Johnson et al. Jan 2010 A1
20100025050 Johnson et al. Feb 2010 A2
20100129766 Hilgers May 2010 A1
20100190127 Ghantiwala et al. Jul 2010 A1
20110083767 Johnson Apr 2011 A1
20110253525 Johnson et al. Oct 2011 A1
Foreign Referenced Citations (29)
Number Date Country
0053596 Jun 1982 EP
0310439 Apr 1989 EP
0836839 Apr 1998 EP
1122526 Aug 2001 EP
1238600 Sep 2002 EP
1779817 May 2007 EP
1967218 Sep 2008 EP
2187951 Sep 1987 GB
48071713 Sep 1973 JP
57161031 Oct 1982 JP
58088200 May 1983 JP
59179771 Oct 1984 JP
07090624 Apr 1995 JP
10173306 Jun 1998 JP
2000185999 Jul 2000 JP
1434314 Oct 1988 SU
WO9842277 Oct 1998 WO
WO9853362 Nov 1998 WO
WO9916387 Apr 1999 WO
WO9962432 Dec 1999 WO
WO0004204 Jan 2000 WO
WO0135865 May 2001 WO
WO0352150 Jun 2003 WO
WO2005084582 Sep 2005 WO
WO2005108635 Nov 2005 WO
WO2006019943 Feb 2006 WO
WO2006044904 Apr 2006 WO
WO2007078304 Jul 2007 WO
WO2008054408 May 2008 WO
Non-Patent Literature Citations (74)
Entry
Johnson, David et al.; U.S. Appl. No. 11/006,501 entitled “Anastomosis device and method,” filed Dec. 6, 2004.
Johnson et al.; U.S. Appl. No. 11/948,852 entitled “Method of alloying reactive elemental components,” filed Nov. 30, 2007.
Antonov et al.; New advances and developments in the Stepnakov method for the growth of shaped crystals; Crystallography Reports; vol. 47; Suppl. 1; 2002; pp. S43-S52.
Brice et al.; Crystal Growth; Ullmann's Encyclopedia of Industrial Chemistry; 2007; Wiley-VCH Verlag GmBH; pp. 1, 29-42, 50.
Buchaillot et al., “Thin film of titanium/nickel shape memory alloy for multi-degree of freedom microactuators”, Seisan Kenkyu, vol. 51, No. 8, 1999, pp. 22-23.
Creuziger et al.; Initial transformation around a notch tip in CuA1Ni: experiment and modeling; Acta Materialia; vol. 56; pp. 518-526; 2008.
Christian et al.; The application of shape memory actuators in anthropomorphic upper limb prostheses; Artif. Organs; vol. 27; No. 5; pp. 473-477; 2003.
Dario et al.; Shape memory alloy microactuators for minimal invasive surgery; Proceedings of SMST-94 Conference; pp. 427-433; Pacific Grove CA; 1994.
ElastametTM brochure from New Discovery Metals; 2007.
ElastametTM website screen capture, accessed Jul. 23, 2008.
Fu et al.; The growth characteristics with a shape memory effect; J. Phys.: Condens. Matter; vol. 4; 1992; pp. 8303-8310.
Gill et al.; Three-Dimensional Thin-Film Shape Memory Alloy Microactuator With Two-Way Effect; Journal of Microelectromechanical Sys.; vol. 11; No. 1; pp. 68-77; Feb. 2002.
http://www.algor.com/news_pub/tech_reports/2005/rubber&foam/default.asp.
Johnson et al., “Application of shape memory alloys: advantages, disadvantages, and limitations,” Micromachining and Microfabrication Process Technology VII, 22-4, Oct. 2001, San Francisco, CA, USA, vol. 4557, pp. 341-351.
Johnson, A. D.; Vacuum-deposited TiNi shape memory film: Characterization and applications in microdevices; J. Micromech. Microeng.; vol. 1; pp. 34-41; 1991.
Krulevitch et al.; Thin film shape memory alloy microactuators; J. Micromech. Microeng.; vol. 5; No. 4; 26 pgs.; 1996.
Martynov, V., “TiNi thin films for microactuators and microdevices: sputter deposition and processing techniques”, Thermec' 2003, Internat'l Conf. on Processing and Manufacturing of Advanced Materials, Jul. 7-11, 2003, Leganes, Madrid, Spain, Materials Science Forum, Jul. 7, 2003 vol. 426-432; pp. 3475-3480.
Morgan; Medical shape memory alloy applications—the market and its products; Materials Science and engineering A 378; 2004; pp. 16-23.
Pauling, Linus, College Chemistry, second edition, W.H. Freeman and Company, San Francisco, 1955, pp. 81-91.
Qingfu et al.; Stabilisation of martensite during training of Cu—Al—Ni single crystals; Journal de Physique IV; Collloqu C2; Supplement to the Journa de Physique III; vol. 5; Feb. 1995; pp. 181-186.
Recarte et al.; Influence of Al and Ni concentration on the martensitic transformation in Cu—Al—Ni shape-memory alloys; Metallurgical and MaterialsTransactions A; vol. 33A; Aug. 2002; pp. 2581-2591.
Schetky, L.M.; Shape-memory alloys; Scientific American, pp. 74-82; 1979.
Sittner et al.; Stress induced martensitic transformations in tension/torsion of CuAlNi single crystal tube; Scripta Materialia; vol. 48; 2003; pp. 1153-1159.
Sutuo et al.; Development of medical guide wire of Cu—Al—Mn-base superelastic alloy with functionally graded characteristics; Mater Res Part B: Appl Biomater; vol. 69B; 2004; pp. 64-69.
Takabayashi et al., “Reversible shape memory alloy film fabricated by RF sputtering”, Materials and Manufacturing Processes, vol. 13, No. 2, 1998, pp. 275-286.
Viahhi et al.; “Robototechnic Constructions Based on Cu—Al—Ni Single Crystal Actuators;” Proceedings of Second International Conference on Shape Memory and Superelastic Technologies; 1997; United States.
Wang et al.; Temperature memory effect in CuAlNi single crystalline and CUZnAl polycrystalline shape memory alloys; Thermochimica Acta; vol. 448; 2006; pp. 69-72.
Yahia et al.; Bioperformance of shape memory alloy single crystals; Bio-Medical Materials and Engineering; vol. 16; 2006; pp. 101-118.
Zhang et al.; Nanoscale pseudoelasticity of single-crystal Cu—Al—Ni shape-memory alloy induced by cyclic nanoindentation; J Mater Sci; vol. 41; 2006; pp. 5021-5024.
Zhang et al.; The variant selection criteria in single-crystal CuAlNi shape memory alloys; Smart Mater. Struct.; vol. 9; 2000; pp. 571-581.
Zhdanov et al.; Thermal stresses in tubes, produced from a melt by the Stepanov method, during their cooling; Journal of Engineering Physics and Thermophysics; vol. 68; No. 1; 1995; pp. 80-89.
Balasundaram et al; Using hydroxyapatite nanoparticles and decreased crystallinity to promote osteoblast adhesion similar to functionalizing with RGD; Biomaterials; vol. 27; 2006; pp. 2798-2805.
Barbucci et al.; Micro and nano-structured surfaces; Journal of Materials Science: Materials in Medicine; vol. 14; 2003; pp. 721-725.
Barbucci et al.; Micropatterned surfaces for the control of endothelial cell behaviour; Bimolecular Engineering; vol. 19; 2002; pp. 161-170.
Brock et al.; Geometric determinants of directional cell motility revealed using microcontact printing; Langmuir; vol. 19; 2003; pp. 1611-1617.
Castner et al.; Biomedical surface science: Foundations to frontiers; Surface Science; vol. 500; 2002; pp. 28-60.
Chen et al.; Geometric control of cell life and death; Science; vol. 276; May 30, 1997; pp. 1425-1428.
Faghihi et al.; The significance of crystallographic texture of titanium alloy substrates on pre-osteoblast responses; Biomaterials; vol. 27; 2006; pp. 3532-3539.
Gall et al.; Tensile deformation of NiTi wires; J Biomed Mater Res; vol. 75A; 2005; pp. 810-823.
Geissler et al.; Patterning: Principles and some new developments; Advanced Materials; vol. 16; No. 15; Aug. 4, 2004; pp. 1249-1269.
Hassel; Surface treatment of NiTi for medical applications; Min. Invas. Ther. & Allied Tech.; vol. 13; No. 4; 2004; pp. 240-247.
Ingber; Tensegrity II. How structural networks influence cellular information processing networks; Journal of Cell Science; vol. 116; 2003; pp. 1397-1408.
Jiang et al.; Directing cell migration with asymmetric micropatterns; PNAS; vol. 102; No. 4; Jan. 25, 2005; pp. 975-978.
Lam et al.; The attachment, proliferation, and wound healing of endothelial and smooth muscle cells on nitinol thin film in vitro; Proc. of the 26th Ann. Intl. Conf. of the IEEE EMBS; San Franciso, CA, USA; Sep. 1-5, 2004; pp. 5044-5046.
Lu et al.; Endothelial cell adhesion on highly controllable compared to random nonostructured titanium surface features; Mater. Res. Soc. Symp. Proc.; vol. 951; 2007.
Magnani et al.; Cell behaviour on chemically microstructured surfaces; Materials Science and Engineering; vol. C 23; 2003; pp. 315-328.
Mai et al.; A microfabricated platform probing cytoskeleton dynamics using mulidirectional topographical cues; Biomed Microdevices; vol. 9; 2007; pp. 523-531.
Miller et al.; PLGA nanometer surface features manipulate fibronectin interactions for improved vascular cell adhesion; Journal of Biomedical Materials Research; Part A; 81A; Issue 3; pp. 678-684; Dec. 22, 2006.
Monsees et al.; Effects of different titanium alloys and nonosize surface patterning on adhesion, differentiation, and orientation of osteoblast-like cells; Cells Tissues Organs, Karger, Basel, CH; vol. 180; No. 2; pp. 81-95; Jan. 1, 2005.
Morra; Biochemical modification of titanium surfaces: peptides and ECM proteins; European Cells and Materials; vol. 12; 2006; pp. 1-15.
Nelson et al.; Degradation of micropatterned surfaces by cell-dependent and -independent processes; Langmuir; Jul. 1, 2002; pp. A-G.
Pattison et al.; Three-dimensional, nano-structured PLGA scaffolds for bladder tissue replacement applications; Biomaterials; vol. 26; 2005; pp. 2491-2500.
Pelton et al.; A guide to shape memory and superelasticity in nitinol medical devices; Min. Invas. Ther. & Allied Tech.; vol. 13; No. 4; 2004; pp. 218-221.
Price et al.; Nanometer surface roughness increases select osteoblast adhesion on carbon nanofiber compacts; J Biomed Mater Res; vol. 70A; 2004; pp. 129-138.
Robertson et al.; Crystallographic texture for tube and plate of the superelastic/shape-memory alloy nitinol used for endovascular stents; J Biomed Mater Res; vol. 72A; 2005; pp. 190-199.
Sagvolden et al.; Cell adhesion force microscopy; Proc. Natl. Acad. Sci. USA; vol. 96; Jan. 1999; pp. 471-476.
Sato et al.; Nanobiotechnology: implications for the future of nanotechnology in orthopedic applications; Expert Rev. Medical Devices; vol. 1; No. 1; 2004; pp. 105-114.
Shaikh-Mohammed et al.; Cell adhesion testing using novel testbeds containing micropatterns of complex nanoengineered multilayer films; Proc. of the 26th Ann. Intl. Conf. of the IEEE EMBS; San Francisco, CA, USA; Sep. 1-5, 2004; pp. 2671-2674.
Stevens et al.; Exploring and engineering the cell surface interface; Science; vol. 310; Nov. 18, 2005; pp. 1135-1138.
Stoeckel et al.; Self-expanding nitinol stents: material and design considerations; Eur. Radiol.; vol. 14; 2004; pp. 292-301.
Thapa et al.; Polymers with nano-dimensional surface features enhance bladder smooth muscle cell adhesion; J. Biomed Mater Res; vol. 67A; 2003; pp. 1374-1383.
Thierry et al.; Effect of surface treatment and sterilization processes on the corrosion behaviour of NiTi shape memory alloy; J. Biomed Mater Res; vol. 51; 2000; pp. 685-693.
Tourovskaia et al.; Micropatterns of chemisorbed cell adhesion-repellent films using oxygen plasma etching and elastomeric masks; Langmuir; vol. 19; 2003; pp. 4754-4764.
Trépanier et al.; Preliminary investigation of the effects of surface treatments on biological response to shape memory NiTi stents; J. Biomed Mater Res (Appl Biomater); vol. 48; 1999; pp. 165-171.
Vastag; Stents stumble—Enthursiasm wanes for drug-coated artery tubes; Science; vol. 171; pp. 394-395; Jun. 23, 2007.
Wang et al.; Control of cytoskeletal mechanics by extracellular matrix, cell shape, and mechanical tension; Biophysical Journal; vol. 66; Jun. 1994; pp. 2181-2189.
Webster et al.; Increased osteoblast adhesion on titanium-coated hydroxylapatite that forms CaTiO3; J Biomed Mater Res; vol. 67A; 2003; pp. 975-980.
Webster et al.; Nanoceramic surface roughness enhances osteoblast and osteoclast functions for improved orthopaedic/dental implant efficacy; Scripta mater.; vol. 44; 2001; pp. 1639-1642.
Webster; Nanotechnology for healing damaged vascular tissue; posted May 4, 2007; www.scitizen.com/screens/blogPage/viewBlog.
Webster; Nonotechnology: Better materials for all implants; Mat. Science Forum; vols. 539-543; 2007; pp. 511-516.
Wirth et al.; Nitinol surface roughness modulates in vitro cell response: a comparison between fibroblasts and osteoblasts; Mat. Science and Eng.; vol. C 25; 2005; pp. 51-60.
Zhang et al.; Biological surface engineering: a simple system for cell pattern formation; Biomaterials; vol. 20; 1999; pp. 1213-1220.
Johnson et al.; U.S. Appl. No. 13/215,438 entitled “Shape setting a shape memory alloy dental arch,” filed Aug. 23, 2011.
Johnson, Alfred David; U.S. Appl. No. 13/601,749 entitled “Fire Sprinkler Valve Actuator,” filed Aug. 31, 2012.
Related Publications (1)
Number Date Country
20110313513 A1 Dec 2011 US
Provisional Applications (1)
Number Date Country
60952818 Jul 2007 US
Divisions (1)
Number Date Country
Parent 12182119 Jul 2008 US
Child 13220522 US